Corebridge Financial Inc. cut its stake in shares of Encompass Health Co. (NYSE:EHC - Free Report) by 4.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 113,989 shares of the company's stock after selling 4,992 shares during the period. Corebridge Financial Inc. owned about 0.11% of Encompass Health worth $10,527,000 at the end of the most recent quarter.
Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Encompass Health by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 10,404,081 shares of the company's stock worth $960,817,000 after acquiring an additional 138,196 shares during the last quarter. Stevens Capital Management LP bought a new position in shares of Encompass Health during the 4th quarter valued at about $257,000. LPL Financial LLC grew its position in shares of Encompass Health by 8.8% during the fourth quarter. LPL Financial LLC now owns 35,558 shares of the company's stock valued at $3,284,000 after purchasing an additional 2,869 shares in the last quarter. Fox Run Management L.L.C. bought a new stake in shares of Encompass Health in the fourth quarter worth about $1,592,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Encompass Health in the fourth quarter worth about $1,893,000. Institutional investors own 97.25% of the company's stock.
Analyst Upgrades and Downgrades
Several equities analysts have weighed in on EHC shares. StockNews.com upgraded Encompass Health from a "hold" rating to a "buy" rating in a report on Saturday, February 15th. Royal Bank of Canada reissued an "outperform" rating and set a $110.00 price objective on shares of Encompass Health in a research note on Tuesday, February 11th. Barclays boosted their target price on Encompass Health from $116.00 to $118.00 and gave the company an "overweight" rating in a research report on Friday, February 7th. William Blair restated an "outperform" rating on shares of Encompass Health in a report on Friday, February 7th. Finally, KeyCorp increased their price objective on Encompass Health from $117.00 to $120.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. Ten research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Encompass Health presently has a consensus rating of "Buy" and a consensus price target of $107.67.
Read Our Latest Stock Report on EHC
Insider Transactions at Encompass Health
In other Encompass Health news, CAO Andrew L. Price sold 5,042 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $98.29, for a total value of $495,578.18. Following the completion of the transaction, the chief accounting officer now directly owns 69,164 shares of the company's stock, valued at approximately $6,798,129.56. The trade was a 6.79 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 2.10% of the company's stock.
Encompass Health Stock Up 0.6 %
Shares of Encompass Health stock traded up $0.62 on Monday, reaching $101.40. The stock had a trading volume of 597,309 shares, compared to its average volume of 649,675. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84. The stock has a market capitalization of $10.21 billion, a P/E ratio of 22.74, a P/E/G ratio of 2.31 and a beta of 0.92. The company has a 50 day moving average price of $98.81 and a 200 day moving average price of $97.52. Encompass Health Co. has a 1 year low of $78.53 and a 1 year high of $104.55.
Encompass Health (NYSE:EHC - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $1.17 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.05 by $0.12. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. As a group, equities research analysts forecast that Encompass Health Co. will post 4.8 EPS for the current year.
Encompass Health Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Tuesday, April 1st will be paid a $0.17 dividend. The ex-dividend date of this dividend is Tuesday, April 1st. This represents a $0.68 dividend on an annualized basis and a yield of 0.67%. Encompass Health's dividend payout ratio (DPR) is 15.25%.
Encompass Health Profile
(
Free Report)
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
Featured Articles
Before you consider Encompass Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Encompass Health wasn't on the list.
While Encompass Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
